Venture Investors

Rivermark Medical specializes in the development of minimally invasive treatments for Benign Prostatic Hyperplasia (BPH), a condition that affects urinary function in men. The company focuses on device therapies designed to effectively alleviate BPH symptoms with minimal side effects, ensuring a swift recovery for patients. Developed by urologists, Rivermark's innovative approach allows for procedures that require little to no downtime and eliminate the need for post-procedural catheters, enabling patients to quickly resume their normal daily activities.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

EarliTec Diagnostics is a digital health company focused on the early identification and treatment of autism spectrum disorder (ASD) and related disabilities in children. The company was developed by prominent researchers from Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University. EarliTec is at the forefront of creating biomarkers that provide insights into how children perceive their environment. Its innovative technology utilizes dynamic quantification of social-visual engagement (DQSVE) to monitor looking behavior that is often undetectable to the naked eye. This capability enables parents, providers, and caregivers to implement personalized and timely therapeutic interventions for children.

ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

Elephas is a live tumor imaging diagnostics company focused on enhancing cancer treatment through personalized therapy determination. The company leverages advancements in cancer biology, multimodal microscopy, engineering, and artificial intelligence to analyze human live tumor fragments. This innovative platform aims to improve clinical decision-making for oncologists, enabling them to tailor treatments to individual patients. Additionally, Elephas seeks to accelerate drug development processes, addressing the urgent need for effective cancer therapies in a rapidly evolving healthcare landscape.

Visana Health is a digital health platform dedicated to enhancing the quality of life for women experiencing severe menstrual pain. The company operates a comprehensive virtual women's health clinic that offers evidence-based treatments and medications designed to alleviate symptoms. By connecting patients with a curated network of expert clinicians specializing in endometriosis and pelvic pain, Visana Health empowers women to take control of their health. The organization aims to address the systemic issues that have long overlooked the needs of women suffering from menstrual pain, drawing on insights from both medical professionals and patients with firsthand experience.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

EnsoData is a healthcare technology startup that leverages artificial intelligence to enhance the diagnosis and treatment of sleep disorders. Its software employs advanced machine learning algorithms to analyze sleep data, enabling clinicians to efficiently score and diagnose conditions such as sleep apnea. By integrating best practices in scoring with innovative algorithms, EnsoData's platform automates the interpretation of complex sleep study data, significantly reducing review times for neurology labs. This efficiency not only streamlines the scoring process but also enhances patient outcomes and increases revenue for healthcare providers.

ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

EnsoData is a healthcare technology startup that leverages artificial intelligence to enhance the diagnosis and treatment of sleep disorders. Its software employs advanced machine learning algorithms to analyze sleep data, enabling clinicians to efficiently score and diagnose conditions such as sleep apnea. By integrating best practices in scoring with innovative algorithms, EnsoData's platform automates the interpretation of complex sleep study data, significantly reducing review times for neurology labs. This efficiency not only streamlines the scoring process but also enhances patient outcomes and increases revenue for healthcare providers.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Eximis Surgical, founded in 2014 and headquartered in Louisville, Colorado, specializes in developing innovative technology for laparoscopic surgery. The company has created a specimen removal device that enables surgeons to efficiently extract large specimens through small incisions. This device utilizes radio frequency (RF) energized cutting wires, which are temporarily held in a containment bag, allowing for quick and safe specimen removal. By integrating seamlessly into existing physician protocols, Eximis Surgical's technology significantly reduces the time required for specimen extraction, minimizes patient discomfort, and ensures safe surgical outcomes. Additionally, the device separates specimens into narrow strips, facilitating the creation of clean tissue segments for accurate pathology identification, thereby enhancing the overall effectiveness of minimally invasive surgery.

Health Scholars, Inc. is a company that specializes in medical simulation training software aimed at enhancing clinical education for healthcare providers. Established in 2017 and based in Westminster, Colorado, the company offers a range of virtual reality (VR) training solutions, including pre-hospital and in-hospital Advanced Cardiovascular Life Support (ACLS) training for first responders and clinicians, respectively. Additionally, Health Scholars provides VR training focused on mitigating surgical fire risks in operating rooms. Their platform is designed to be user-friendly and scalable across healthcare systems, allowing for the effective management and delivery of interactive training content. This approach not only offers a cost-effective solution but also enriches the educational experience for medical professionals.

SkySpecs, Inc. is a technology company based in Ann Arbor, Michigan, with an additional office in Amsterdam, Netherlands, that specializes in automating operations and maintenance for the wind energy industry through unmanned aerial vehicles. Founded in 2012, the company provides a range of services including analytics, wind turbine blade services, and engineering projects. Its offerings also encompass collaborative software solutions for managing and analyzing data from various sources, as well as digitization and planning for repair campaigns. Notably, SkySpecs has developed Horizon, a reporting software that serves as a central repository for operations and maintenance data related to wind turbine blades, facilitating task management, communication with third parties, and execution of large-scale repair projects. By leveraging its industry expertise and innovative technologies, SkySpecs aims to enhance productivity and efficiency for its clients within the renewable energy sector.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Eximis Surgical, founded in 2014 and headquartered in Louisville, Colorado, specializes in developing innovative technology for laparoscopic surgery. The company has created a specimen removal device that enables surgeons to efficiently extract large specimens through small incisions. This device utilizes radio frequency (RF) energized cutting wires, which are temporarily held in a containment bag, allowing for quick and safe specimen removal. By integrating seamlessly into existing physician protocols, Eximis Surgical's technology significantly reduces the time required for specimen extraction, minimizes patient discomfort, and ensures safe surgical outcomes. Additionally, the device separates specimens into narrow strips, facilitating the creation of clean tissue segments for accurate pathology identification, thereby enhancing the overall effectiveness of minimally invasive surgery.

Invenra Inc. is a biotechnology company based in Madison, Wisconsin, founded in 2011. The company specializes in discovering and developing biologics, particularly antibodies and their derivatives. Invenra employs a unique drug discovery platform that integrates cell-free expression technology with extreme miniaturization, allowing for the screening of a vast number of full-length antibodies in phenotypic assays. This innovative approach enables the identification and optimization of human multi-specific antibodies for therapeutic applications, including treatments for cancer, Alzheimer's disease, and diabetes. Invenra's team consists of experienced scientists with expertise in genomics, biochemistry, and bioengineering, blending advanced research with practical applications in the development of new biologic drugs.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

SkySpecs, Inc. is a technology company based in Ann Arbor, Michigan, with an additional office in Amsterdam, Netherlands, that specializes in automating operations and maintenance for the wind energy industry through unmanned aerial vehicles. Founded in 2012, the company provides a range of services including analytics, wind turbine blade services, and engineering projects. Its offerings also encompass collaborative software solutions for managing and analyzing data from various sources, as well as digitization and planning for repair campaigns. Notably, SkySpecs has developed Horizon, a reporting software that serves as a central repository for operations and maintenance data related to wind turbine blades, facilitating task management, communication with third parties, and execution of large-scale repair projects. By leveraging its industry expertise and innovative technologies, SkySpecs aims to enhance productivity and efficiency for its clients within the renewable energy sector.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Elucent Medical LLC is focused on improving breast cancer treatment processes through innovative technology. Founded in 2014 and headquartered in Brookfield, Wisconsin, the company has developed a wireless marker tag and detection system that enhances the surgical excision of breast abnormalities. This advanced surgical navigation technology allows for real-time data processing, enabling surgeons to accurately locate tumor margins and enhance the precision of procedures. By eliminating the need for metal clips, Elucent Medical's solutions aim to simplify breast cancer treatment, making it more accessible and affordable while helping to preserve patients' breasts during surgery. The company's offerings benefit both healthcare providers and patients by improving overall surgical outcomes.

TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, established in 2013. The company specializes in developing non-invasive diagnostic tests aimed at monitoring the health of transplanted organs in patients who have undergone solid organ transplants. Utilizing advanced cell-free DNA (cf-DNA) technology, TAI Diagnostics' test quantifies donor-specific cf-DNA released into the bloodstream from injured cells of a transplanted organ, allowing for early detection of organ rejection. This innovative approach enables physicians to perform regular surveillance biopsies, ultimately enhancing patient care and outcomes in the transplant community. The company is situated in the Milwaukee County Research Park, adjacent to significant medical institutions, positioning it within a vibrant healthcare ecosystem.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

SkySpecs, Inc. is a technology company based in Ann Arbor, Michigan, with an additional office in Amsterdam, Netherlands, that specializes in automating operations and maintenance for the wind energy industry through unmanned aerial vehicles. Founded in 2012, the company provides a range of services including analytics, wind turbine blade services, and engineering projects. Its offerings also encompass collaborative software solutions for managing and analyzing data from various sources, as well as digitization and planning for repair campaigns. Notably, SkySpecs has developed Horizon, a reporting software that serves as a central repository for operations and maintenance data related to wind turbine blades, facilitating task management, communication with third parties, and execution of large-scale repair projects. By leveraging its industry expertise and innovative technologies, SkySpecs aims to enhance productivity and efficiency for its clients within the renewable energy sector.

TAI Diagnostics, Inc. is a biotechnology company based in Wauwatosa, Wisconsin, established in 2013. The company specializes in developing non-invasive diagnostic tests aimed at monitoring the health of transplanted organs in patients who have undergone solid organ transplants. Utilizing advanced cell-free DNA (cf-DNA) technology, TAI Diagnostics' test quantifies donor-specific cf-DNA released into the bloodstream from injured cells of a transplanted organ, allowing for early detection of organ rejection. This innovative approach enables physicians to perform regular surveillance biopsies, ultimately enhancing patient care and outcomes in the transplant community. The company is situated in the Milwaukee County Research Park, adjacent to significant medical institutions, positioning it within a vibrant healthcare ecosystem.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

FluGen, Inc. is a biopharmaceutical company focused on the prevention and treatment of influenza and other respiratory pathogens. Founded in 2007 and based in Madison, Wisconsin, FluGen develops vaccines to combat seasonal and pandemic influenza. Its primary product, RedeeFlu, is a nasal spray vaccine designed to protect against influenza, utilizing a live, single replication virus that has a portion of the M2 segment deleted. This innovative approach allows for effective prevention of influenza and supports healthcare professionals in controlling potential pandemics. The company is actively engaged in clinical-stage vaccine development to address both seasonal influenza and emerging respiratory threats.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

HealthMyne, Inc. is a healthcare informatics company based in Madison, Wisconsin, established in 2013. It specializes in providing innovative imaging solutions and analytics primarily for cancer care providers. The company's technology enhances clinical decision-making by offering real-time, evidence-based imaging insights that facilitate improved patient care while also reducing delivery costs. HealthMyne's platform includes features such as tumor image manipulation, automatic tumor staging, specialized reporting, and management of incidental findings, all aimed at streamlining clinical workflows. By integrating electronic health records and image repositories, HealthMyne supports physicians in diagnosing and treating patients more effectively, ultimately enhancing clinical collaboration and quality assurance in patient management.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

Thalchemy Corp., established in 2012 and based in Madison, Wisconsin, specializes in developing neurally-inspired algorithms and accelerators. These innovations mimic the mammalian thalamus' operation, enabling continuous sensory processing in battery-operated devices like smartphones. Thalchemy's technology extends battery life, facilitates power-optimized voice and gesture control, and allows for the creation of new always-on applications. It also offers a simplified development approach with an automated, zero-lines-of-code system. Additionally, Thalchemy's technology can be used in healthcare monitoring systems, detecting and alerting in case of falls or irregular heartbeats.

Prevacept Infection Control is a clinical-stage company focused on developing and commercializing products that prevent infections associated with indwelling catheters.

Thalchemy Corp., established in 2012 and based in Madison, Wisconsin, specializes in developing neurally-inspired algorithms and accelerators. These innovations mimic the mammalian thalamus' operation, enabling continuous sensory processing in battery-operated devices like smartphones. Thalchemy's technology extends battery life, facilitates power-optimized voice and gesture control, and allows for the creation of new always-on applications. It also offers a simplified development approach with an automated, zero-lines-of-code system. Additionally, Thalchemy's technology can be used in healthcare monitoring systems, detecting and alerting in case of falls or irregular heartbeats.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Neurovance, Inc. is a clinical-stage neuroscience company based in Cambridge, Massachusetts, that specializes in developing therapies for attention deficit hyperactivity disorder (ADHD) in both adults and children. Founded in 2009, the company focuses on centanafadine, a triple reuptake inhibitor that modulates the activity of norepinephrine, dopamine, and serotonin to improve focus and reduce inattention and disorganization in ADHD patients. As of March 31, 2017, Neurovance operates as a subsidiary of Otsuka America, Inc., and has received venture capital funding from various investors, including Novartis Venture Fund and the State of Wisconsin Investment Board.

NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, founded in 2012. It specializes in developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. The company’s platform provides in-vitro testing tools that enhance the efficiency and cost-effectiveness of laboratory operations. By improving the capabilities of laboratory professionals, NeuMoDx aims to increase the adoption of molecular diagnostic testing among medical providers, facilitating earlier and more accurate disease identification and treatment. In 2013, NeuMoDx changed its name from Molecular Systems Corporation and has since become a subsidiary of QIAGEN N.V.

UpTo, Inc. is a company that specializes in developing a social calendar application for smartphones. Founded in 2011 and based in Detroit, Michigan, UpTo provides a platform that allows users to publish and manage their organization's calendar while privately connecting with friends, family, and colleagues to share events selectively. The application offers a streamlined view of important upcoming events, eliminating clutter and focusing on what matters most. Users can easily add events, syncing seamlessly across both mobile and web platforms, and can integrate with existing calendars such as Google Calendar and Outlook. The service is designed to cater to both individuals and organizations, enhancing the way they manage and share their schedules.

Madison Vaccines, Inc. is a biopharmaceutical company based in the United States that specializes in developing therapeutic plasmid DNA vaccines targeting prostate cancer and bone metastases. The company is focused on creating two distinct vaccines designed for patients with prostate cancer, along with a diagnostic test aimed at identifying those who would benefit most from these therapies. Madison Vaccines' immune-activating therapies work by stimulating the immune system to eliminate residual tumor cells, thereby preventing the progression to bone metastases and delaying the need for more invasive treatments such as castration therapies. This approach aims to improve patient outcomes and enhance quality of life by facilitating earlier interventions in the cancer treatment process.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer treatment. The company's lead candidate, CLR 131, is a phospholipid drug conjugate (PDC) currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and other B-cell malignancies. Additionally, Cellectar is developing CLR 1900, a PDC aimed at targeting solid tumors. The company employs a proprietary PDC delivery platform, which combines lipid-like molecules with radioisotopes to enhance the targeting of malignant cells while minimizing effects on healthy tissue. Cellectar has established collaborative programs with various organizations to advance the development of multiple PDCs, further expanding its portfolio. Founded in 2002 and originally named Novelos Therapeutics, Cellectar Biosciences is headquartered in Florham Park, New Jersey.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Tissue Regeneration Systems Inc. is a start-up medical device company based in Plymouth, Michigan, with an additional office in Kirkland, Washington, and a research facility in Ann Arbor, Michigan. Founded in 2005, the company specializes in a skeletal reconstruction and bone regeneration technology licensed from the Universities of Michigan and Wisconsin. This innovative technology is applicable in various medical fields, including craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and the delivery of bone growth factors. The company's devices utilize a biodegradable polyester polymer to facilitate spinal implants and repair damaged bones, enhancing surgical outcomes for conditions such as fractured orbital sockets and facial deformities. Tissue Regeneration Systems has successfully completed bench and animal testing and has filed initial regulatory submissions to the FDA, with expectations to commercialize its products in the United States and begin generating revenue in the coming years.

Nextt, Inc. is a technology company based in Madison, Wisconsin, that specializes in developing web and mobile application software. The company's primary offering is a private networking platform designed to help close friends connect and organize social activities more effectively. By providing tools for sharing ideas and coordinating plans, Nextt simplifies the social planning process, allowing users to manage details such as participants, activities, timing, and locations in a secure environment. This approach encourages users to prioritize quality time with friends and fosters offline interactions.

UpTo, Inc. is a company that specializes in developing a social calendar application for smartphones. Founded in 2011 and based in Detroit, Michigan, UpTo provides a platform that allows users to publish and manage their organization's calendar while privately connecting with friends, family, and colleagues to share events selectively. The application offers a streamlined view of important upcoming events, eliminating clutter and focusing on what matters most. Users can easily add events, syncing seamlessly across both mobile and web platforms, and can integrate with existing calendars such as Google Calendar and Outlook. The service is designed to cater to both individuals and organizations, enhancing the way they manage and share their schedules.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

NetSocket is a company that focuses on virtualized, software-defined networking, offering solutions that enhance network-service assurance for unified communication. Its flagship product, the Netsocket Virtual Network (NVN), delivers on the promises of software-defined networking (SDN) and network function virtualization (NFV) through advanced automation applications operating on a fully virtualized network infrastructure. Additionally, NetSocket developed the Cloud Experience Manager, a tool designed to optimize service management for Microsoft Lync. Founded in 2006 and based in Plano, Texas, NetSocket aims to improve the efficiency and reliability of network services.

BlueWillow Biologics, a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializes in the development of intranasal vaccines and anti-infective products utilizing its patented nanotechnology platform. The company's innovative NanoStat vaccine technology incorporates a unique oil-in-water nanoemulsion, allowing for the effective delivery and adjuvant of various antigens. BlueWillow focuses on vaccines for respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, and HIV, as well as providing NanoBio Protect, a nasal antiseptic solution. The company also has a licensing agreement with Merck for the use of its adjuvant in intranasal vaccines for respiratory syncytial virus (RSV) and seasonal influenza. Founded in 1999 as a spin-off from the University of Michigan, BlueWillow Biologics aims to enhance mucosal immunity through its advanced vaccine technology.

ReShape Medical Inc. is a medical device company headquartered in San Clemente, California, specializing in non-surgical weight loss solutions. The company offers the ReShape Integrated Dual Balloon System, which employs dual balloon technology to aid weight loss in adults with a Body Mass Index (BMI) of 30-40 who have not achieved success with diet and exercise alone. This procedure is complemented by a personalized weight loss program that lasts one year. The company's product line includes the FDA-approved Lap-Band System, a minimally invasive treatment for obesity, and the investigational ReShape Vest System, designed to wrap around the stomach and induce weight loss without permanently altering patient anatomy. ReShape Medical's portfolio aims to provide effective alternatives to invasive surgical procedures for managing obesity and related metabolic diseases. The company operates as a subsidiary of EnteroMedics Inc., having undergone a name change in 2017.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

Aerpio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, focused on developing innovative compounds for the treatment of ocular diseases and diabetic complications. The company's lead candidate, razuprotafib, is a small molecule activator of the Tie2 pathway that has completed a Phase IIb clinical trial for diabetic retinopathy. Additionally, Aerpio is advancing ARP-1536, a humanized monoclonal antibody in preclinical development for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently undergoing a Phase 1b trial for inflammatory bowel disease. Furthermore, the company is developing a bispecific antibody for the treatment of wet age-related macular degeneration and diabetic macular edema. Aerpio has also partnered with Quantum Leap Healthcare Collaborative to evaluate razuprotafib's potential in treating acute respiratory distress syndrome in COVID-19 patients. Founded in 2011, Aerpio Pharmaceuticals aims for rapid development of its promising therapies.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

Euthymics Bioscience, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for central nervous system disorders. Established in 2009, the company is dedicated to addressing significant unmet medical needs, particularly in major depressive disorder (MDD) and alcohol use disorder (AUD). Euthymics is advancing its lead product, EB-1010, aimed at improving treatment outcomes for patients with depression who do not respond adequately to standard therapies such as selective serotonin reuptake inhibitors (SSRIs). This treatment seeks to enhance efficacy while minimizing common side effects associated with traditional antidepressants, including weight gain and sexual dysfunction. Additionally, Euthymics is exploring therapeutic options for smoking cessation and impulsivity, targeting withdrawal symptoms and cravings in affected individuals.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, that specializes in discovering and developing small molecule drugs aimed at addressing unmet medical needs associated with central nervous system disorders. Founded in 2004, the company focuses primarily on serious chronic neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Its drug portfolio features candidates designed for treating cognitive impairments and blocking disease processes in conditions such as Progressive Supranuclear Palsy. Notable projects include MCD-386CR, which targets neurodegenerative diseases, and MCD-386/glycopyrrolate, aimed at preventing Alzheimer's in genetically defined presymptomatic mutation carriers. Additionally, the company is developing MI-08-016/035 for common neurodegenerative diseases and MI-10-022 to address significant unmet needs in schizophrenia.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for kidney diseases. The company's primary product is Auryxia, a ferric citrate formulation approved for managing serum phosphorus levels in adult patients with chronic kidney disease, both on dialysis and those not requiring dialysis, as well as for treating iron deficiency anemia. Additionally, Akebia is advancing vadadustat, an oral therapy that is currently in Phase III clinical development for treating anemia associated with chronic kidney disease. The company has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in various global markets, alongside a research and licensing agreement with Janssen Pharmaceutica NV for related compounds. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.

BlueWillow Biologics, a clinical-stage biopharmaceutical company based in Ann Arbor, Michigan, specializes in the development of intranasal vaccines and anti-infective products utilizing its patented nanotechnology platform. The company's innovative NanoStat vaccine technology incorporates a unique oil-in-water nanoemulsion, allowing for the effective delivery and adjuvant of various antigens. BlueWillow focuses on vaccines for respiratory and sexually transmitted diseases, including pertussis, pandemic influenza, anthrax, and HIV, as well as providing NanoBio Protect, a nasal antiseptic solution. The company also has a licensing agreement with Merck for the use of its adjuvant in intranasal vaccines for respiratory syncytial virus (RSV) and seasonal influenza. Founded in 1999 as a spin-off from the University of Michigan, BlueWillow Biologics aims to enhance mucosal immunity through its advanced vaccine technology.

ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.

LensX Lasers is a developer of surgical lasers used for the reparation of cataracts.

Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, that specializes in discovering and developing small molecule drugs aimed at addressing unmet medical needs associated with central nervous system disorders. Founded in 2004, the company focuses primarily on serious chronic neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Its drug portfolio features candidates designed for treating cognitive impairments and blocking disease processes in conditions such as Progressive Supranuclear Palsy. Notable projects include MCD-386CR, which targets neurodegenerative diseases, and MCD-386/glycopyrrolate, aimed at preventing Alzheimer's in genetically defined presymptomatic mutation carriers. Additionally, the company is developing MI-08-016/035 for common neurodegenerative diseases and MI-10-022 to address significant unmet needs in schizophrenia.

Silatronix, Inc. specializes in the development of organosilicon (OS) compounds and formulations for use in energy storage devices, particularly in rechargeable and non-rechargeable lithium-ion batteries. Founded in 2007 and based in Madison, Wisconsin, the company focuses on creating patented materials that enhance battery performance by extending cell life, increasing capacity, and allowing higher charge voltages. Silatronix's technology combines expertise in organosilicon compounds and nanostructured electrodes, making its products suitable for a variety of applications, including portable electronics, electric vehicles, and utility-scale energy storage. The company's innovations support advancements in battery technology, contributing to more efficient and effective energy solutions.

Tissue Regeneration Systems Inc. is a start-up medical device company based in Plymouth, Michigan, with an additional office in Kirkland, Washington, and a research facility in Ann Arbor, Michigan. Founded in 2005, the company specializes in a skeletal reconstruction and bone regeneration technology licensed from the Universities of Michigan and Wisconsin. This innovative technology is applicable in various medical fields, including craniomaxillofacial surgery, orthopedic surgery, spine fusion surgery, and the delivery of bone growth factors. The company's devices utilize a biodegradable polyester polymer to facilitate spinal implants and repair damaged bones, enhancing surgical outcomes for conditions such as fractured orbital sockets and facial deformities. Tissue Regeneration Systems has successfully completed bench and animal testing and has filed initial regulatory submissions to the FDA, with expectations to commercialize its products in the United States and begin generating revenue in the coming years.

At Nerites, they combine world class technology with a management team that has a proven track record of bringing technical innovation to market. The company was founded in 2004 to commercialize a new generation of synthetic biomaterials that can enhance natural tissue repair, reduce complications from traditional devices, and degrade safely when they are no longer needed.

NeuWave Medical, founded in 2004 and headquartered in Madison, Wisconsin, specializes in the development of energy-based minimally invasive medical devices designed to treat various serious medical conditions. The company's founders, both engineers and physician-scientists, leverage their expertise to identify clinical needs and create effective solutions that prioritize safety and efficacy. NeuWave Medical aims to produce high-quality devices that are preferred by leading physicians and medical centers globally.

Pattern Insight specializes in advanced data mining and analysis technologies tailored for engineering and IT data. The company offers two main products: Log Insight and Code Insight. Log Insight is a Big Data analytics and log management platform that enables real-time analysis of large volumes of machine-generated data, making it suitable for operational analytics in both traditional and cloud data center environments. Code Insight focuses on identifying and eliminating known defects in source code prior to release, thereby enhancing software quality. The company has established a client base that includes notable names such as Cisco, Intel, Qualcomm, Tellabs, and Motorola. In July 2012, VMware acquired Pattern Insight, further integrating its innovative solutions into the tech landscape.

Cellectar Biosciences is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for cancer treatment. The company's lead candidate, CLR 131, is a phospholipid drug conjugate (PDC) currently undergoing Phase II clinical trials for patients with relapsed or refractory multiple myeloma and other B-cell malignancies. Additionally, Cellectar is developing CLR 1900, a PDC aimed at targeting solid tumors. The company employs a proprietary PDC delivery platform, which combines lipid-like molecules with radioisotopes to enhance the targeting of malignant cells while minimizing effects on healthy tissue. Cellectar has established collaborative programs with various organizations to advance the development of multiple PDCs, further expanding its portfolio. Founded in 2002 and originally named Novelos Therapeutics, Cellectar Biosciences is headquartered in Florham Park, New Jersey.

Deltanoid Pharmaceuticals, Inc. is a biopharmaceutical company based in Madison, Wisconsin, dedicated to the research, development, and commercialization of therapies for various human diseases, particularly focusing on renal diseases, osteoporosis, and skin conditions. Founded in 1999, the company specializes in vitamin D analogs and related compounds, aiming to advance selected therapies through the early stages of drug development. Notable products include DP001, designed for treating secondary hyperparathyroidism in chronic kidney disease patients undergoing hemodialysis, and DP006 for acne treatment. Deltanoid seeks partnerships for the later stages of development and commercialization, and it currently has an agreement with Novadiol, Inc. to develop a vitamin D therapy. Through its innovative approach, the company aims to enhance health outcomes for patients by unlocking the potential of vitamin D receptor-targeted therapies.

Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, that specializes in producing hydrocarbon chemicals and fuels from plant sugars. Utilizing its BioForming technology, the company converts plant-based sugars into a variety of hydrocarbon products that are chemically identical to those derived from petroleum, including gasoline, diesel, jet fuel, and various chemicals used in plastics and fibers. The feedstocks for its processes include bio-based materials such as beet sugar, sugar cane, and corn starch, as well as cellulosic sources like bagasse, corn stover, grasses, and wood. Virent also produces bio-paraxylene, bio-toluene, and bio-benzene, along with Bio-Aromatic 100, a versatile aromatic solvent used across multiple industries like paints, textiles, and construction. The company has established strategic partnerships with notable firms including Royal Dutch Shell and The Coca-Cola Company, enhancing its position in the renewable energy sector. Virent was founded in 2002 and operates as a subsidiary of Marathon Petroleum Corporation.

ProCertus BioPharm, Inc., an oncology-based pharmaceutical company, develops therapeutics to protect cancer patients from the side effects of radiotherapy and chemotherapy in the United States. Its products include ProDermaCel that protects cancer patients from chemotherapy- and radiotherapy-induced alopecia; DermX, which prevents radiotherapy-induced dermatitis; and OralX that provides protection against chemotherapy- and radiotherapy- induced oral mucositis. ProCertus BioPharm, Inc. was founded in 1997 and is based in Madison, Wisconsin.

Incept BioSystems develops innovative microscale technologies that provide fertility specialists breakthrough capabilities to treat infertility. Our technologies improve the in vitro manipulation, performance, and viability of high-value cells, and our mission is to set the standard for next-generation clinical devices for the Assisted Reproductive Technology (ART) laboratory. Like many specialized cells, human embryos typically behave much differently while in vitro than they would in the body, and this performance gap can limit their developmental growth and potentially their viability. Incept’s System for Microfluidic Assisted Reproductive Technology (SMART) platform is the first to deliver unique control of in vitro cell culture environments so that fertility specialists can offer patients new hope in starting a family.

Mithridion, Inc. is a biopharmaceutical company based in Madison, Wisconsin, that specializes in discovering and developing small molecule drugs aimed at addressing unmet medical needs associated with central nervous system disorders. Founded in 2004, the company focuses primarily on serious chronic neurodegenerative diseases, including Alzheimer's disease and schizophrenia. Its drug portfolio features candidates designed for treating cognitive impairments and blocking disease processes in conditions such as Progressive Supranuclear Palsy. Notable projects include MCD-386CR, which targets neurodegenerative diseases, and MCD-386/glycopyrrolate, aimed at preventing Alzheimer's in genetically defined presymptomatic mutation carriers. Additionally, the company is developing MI-08-016/035 for common neurodegenerative diseases and MI-10-022 to address significant unmet needs in schizophrenia.

Virent Energy Systems, Inc. is an energy technology company based in Madison, Wisconsin, that specializes in producing hydrocarbon chemicals and fuels from plant sugars. Utilizing its BioForming technology, the company converts plant-based sugars into a variety of hydrocarbon products that are chemically identical to those derived from petroleum, including gasoline, diesel, jet fuel, and various chemicals used in plastics and fibers. The feedstocks for its processes include bio-based materials such as beet sugar, sugar cane, and corn starch, as well as cellulosic sources like bagasse, corn stover, grasses, and wood. Virent also produces bio-paraxylene, bio-toluene, and bio-benzene, along with Bio-Aromatic 100, a versatile aromatic solvent used across multiple industries like paints, textiles, and construction. The company has established strategic partnerships with notable firms including Royal Dutch Shell and The Coca-Cola Company, enhancing its position in the renewable energy sector. Virent was founded in 2002 and operates as a subsidiary of Marathon Petroleum Corporation.

Chromatin is a biotech company focused on developing and marketing innovative technologies and products across agricultural, energy, chemical, nutritional, and pharmaceutical sectors. The company specializes in hybrid, drought-tolerant sorghum seeds, utilizing advanced breeding methodologies to create next-generation sorghum that meets the rising demand for sustainable agricultural practices. By combining diverse sorghum varieties, Chromatin produces seeds that can thrive on more than 80% of the world's agricultural land, supporting farmers in optimizing crop production for both traditional agriculture and bio-industrial applications. The company aims to address key societal challenges, enhancing agricultural productivity and contributing to renewable energy resources.

ZyStor Therapeutics, Inc. is a privately-held biotechnology company focused on developing enzyme replacement therapies for lysosomal storage diseases. The company specializes in creating innovative replacement technologies that enhance the delivery of therapeutics designed to substitute for missing lysosomal enzymes. These therapies aim to address the needs of patients suffering from genetic disorders characterized by lysosomal storage dysfunction.

Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Chromatin is a biotech company focused on developing and marketing innovative technologies and products across agricultural, energy, chemical, nutritional, and pharmaceutical sectors. The company specializes in hybrid, drought-tolerant sorghum seeds, utilizing advanced breeding methodologies to create next-generation sorghum that meets the rising demand for sustainable agricultural practices. By combining diverse sorghum varieties, Chromatin produces seeds that can thrive on more than 80% of the world's agricultural land, supporting farmers in optimizing crop production for both traditional agriculture and bio-industrial applications. The company aims to address key societal challenges, enhancing agricultural productivity and contributing to renewable energy resources.

Intersymbol Communications, Inc. specializes in the development and manufacturing of high-speed physical layer components designed for next-generation broadband networking systems. The company focuses on advanced electronic dispersion compensation solutions and creates high-speed optical receiver integrated circuits for long-haul and metro optical networks. Their innovative products enhance bandwidth and extend reach while reducing power consumption, leading to significant cost savings for network providers during deployment. By incorporating custom signal processing techniques and specialized architectures, Intersymbol Communications addresses the evolving demands of modern optical data transmission.

Celleration Inc. is a medical device company based in Eden Prairie, Minnesota, founded in 1999. The company specializes in developing and commercializing therapeutic ultrasound technologies for wound care. Its flagship product, the MIST Therapy System, employs low-frequency ultrasound delivered through a saline mist to promote healing by penetrating the wound bed and stimulating cellular activity. Unlike traditional wound treatments, which primarily address the surface, MIST Therapy targets deeper layers to enhance the healing process. Celleration received FDA clearance for this therapy in 2005 and has successfully introduced it to the U.S. market, demonstrating significant clinical and economic benefits across numerous healthcare facilities. To date, over one million MIST Therapy treatments have been administered, positively impacting the lives of more than 65,000 patients. The company operates as a subsidiary of Alliqua BioMedical, Inc.

Roche NimbleGen specializes in providing a range of products and services for the life science research market, particularly in DNA sequencing and microarray technology. The company offers the SeqCap EZ system, which allows for exome enrichment in a single test tube, along with various design options and reagents to facilitate workflow. Additionally, Roche NimbleGen has developed the SeqCap Epi system for DNA methylation assessment at single-base resolution, and it supplies preparation and adapter kits for library construction. Their proprietary Maskless Array Synthesis technology enables the creation of custom high-density DNA arrays, enhancing the quality and data yield of sequencing efforts. The company also provides a suite of DNA microarray products for applications such as comparative genomic hybridization and gene expression analysis, alongside technical support services. Founded in 1999 and based in Madison, Wisconsin, Roche NimbleGen operates as a subsidiary of Roche Holding AG.

Corona Optical Systems is a high-technology company based in Lombard, Illinois, with additional facilities in Eau Claire, Wisconsin, and San Jose, California. Founded in February 2000, the company specializes in the development and manufacturing of optoelectronic components and subsystems designed for carrier-class equipment. Its primary focus includes creating parallel optical modules that are utilized in switching and routing technologies. As a privately held corporation, Corona has attracted venture capital funding to support its growth, including a significant institutional investment round in 2001 led by Intel Capital and involving several other prominent venture firms.

IntraLase Corporation is a leader in the first step of LASIK surgery, the most common means of surgical vision correction. They design, develop and market a laser, related software and disposable devices used to create a cut of tissue across the cornea of a patient’s eye, or a corneal flap, which is the first step in LASIK surgery. Their advanced laser technology improves the safety, precision and visual acuity of LASIK surgery by providing a computer-controlled laser solution as an alternative to the traditional method of creating the corneal flap using a hand-held mechanical, metal-bladed device called a microkeratome. They believe their product offering will become the new standard of care for corneal flap creation. As of April 2, 2007, IntraLase Corp. was acquired by Advanced Medical Optics Inc.

SoftSwitching Technologies specializes in power quality and monitoring solutions tailored for industries such as semiconductor, food, beverage, and automotive. The company provides a range of products, including battery-free DySC systems, intelligent I-Sense sensors that detect the timing and duration of voltage sags, and Grid Alert event notifications, which are part of a global power reporting network. Their offerings are designed to identify and mitigate brief power disruptions, thereby enhancing operational uptime and efficiency in manufacturing processes. Overall, SoftSwitching Technologies aims to deliver effective and scalable solutions that address the critical power quality needs of various sectors.

Gala Biotech, established in 1996 and located in Middleton, Wisconsin, specializes in biopharmaceutical manufacturing and molecular biology. The company, which has grown to over 40 employees, including 16 PhDs, is known for its proprietary GPEx® technology, which facilitates the rapid creation of stable, high-expressing mammalian cell lines for various gene products. Originally focused on producing pharmaceutical proteins in the milk of transgenic cows, Gala has adapted its gene insertion technology to support the increasing demand for the discovery and stable expression of therapeutic proteins. This technology plays a crucial role in helping biotech researchers overcome the challenges associated with clinical development. To enhance its capabilities, Gala has established a 43,000 square-foot facility dedicated to GPEx®-based cell line development and cGMP-compliant protein production, reinforcing its commitment to meeting the needs of its biopharmaceutical partners.

Alfalight specializes in the design and manufacture of high-power diode lasers tailored for industrial, defense, and telecommunications applications. The company utilizes advanced aluminum-free active region (ALFA) laser structures, which contribute to the production of laser diodes that are noted for their high reliability and efficiency. Alfalight's product range includes short-wave infrared, near-infrared, and visible lasers, alongside various laser and electro-optical systems. These innovations position Alfalight as a key player in meeting the demands of both security and telecommunication sectors.

TomoTherapy specializes in developing and marketing advanced radiation therapy solutions for cancer treatment, addressing a wide range of conditions from common to complex. The company's key offering is the TomoTherapy platform, which integrates CT imaging with conformal radiation therapy to deliver precise treatments while minimizing radiation exposure to healthy tissue. Their product lineup includes the Hi·Art treatment system, known for its extensive use in delivering CT-guided, helical intensity-modulated radiation therapy (IMRT), and the TomoHD treatment system, which allows cancer centers to treat a diverse patient population with a single device. Additionally, the TomoMobile relocatable solution enhances access to advanced cancer care. With over 350 systems in operation across 24 countries, TomoTherapy serves a global clientele that includes cancer care centers, universities, and community hospitals.